Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials: A Systematic Review and Meta-analysis.

ABSTRACT:

Importance

The log-rank test is considered the criterion standard for comparing 2 survival curves in pivotal registrational trials. However, with novel immunotherapies that often violate the proportional hazards assumptions over time, log-rank can lose power and may fail to detect treatment benefit. The MaxCombo test, a combination of weighted log-rank tests, retains power under different types of nonproportional hazards. The difference in restricted mean survival time (dRMST) test is frequently proposed as an alternative to the log-rank under nonproportional hazard scenarios.

Objective

To compare the log-rank with the MaxCombo and dRMST in immuno-oncology trials to evaluate their performance in practice.

Data sources

Comprehensive literature review using Google Schol

SUBMITTER: Mukhopadhyay P 

PROVIDER: S-EPMC9305601 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature